In prostate cancer, the most important pathway upregulated through CTR activation is cAMP, leading to a higher invasiveness due to the degradation of extracellular matrix by PKA and urokinase-plasminogen A system (Thomas et al., 2006). The gene discussed is CALCR; the disease is prostate carcinoma.